An anti-HER2 antibody–drug conjugate that binds HER2 on tumor cells and delivers a cytotoxic payload.
Trastuzumab-based anti-HER2 antibody-drug conjugate linked via a cleavable linker to a camptothecin-derived topoisomerase I inhibitor (rezetecan). After HER2 binding and internalization, linker cleavage releases the payload, which stabilizes Topo I-DNA complexes, causing DNA strand breaks, replication arrest, and apoptosis in HER2-expressing tumor cells.
The ADC binds HER2 on target cells, is internalized, and upon linker cleavage releases a camptothecin-derived topoisomerase I inhibitor that traps Topo I–DNA complexes, causing DNA breaks, replication arrest, and apoptosis in HER2-expressing cells.
CD19‑directed antibody‑drug conjugate that delivers a pyrrolobenzodiazepine (PBD) cytotoxic payload to B cells.
Humanized anti‑CD19 monoclonal antibody linked via a cleavable linker to a pyrrolobenzodiazepine (PBD) dimer. After binding CD19 on B cells and internalization, the linker is cleaved to release the PBD payload, which binds the DNA minor groove and forms interstrand cross‑links (N2 of guanine), blocking DNA replication and inducing cytotoxicity in CD19‑expressing tumor cells.
ADC binds CD19, is internalized, and releases a PBD dimer that forms DNA interstrand cross-links (minor groove, N2 of guanine), blocking replication and killing the CD19+ cell.
A TROP2-targeting antibody–drug conjugate that binds TROP2 on tumor cells to deliver a cytotoxic payload.
Binds TROP2 on tumor cells, undergoes receptor-mediated internalization, and releases a cytotoxic payload intracellularly to kill TROP2-expressing cancer cells.
The ADC binds TROP2, is internalized via receptor-mediated endocytosis, and releases a cytotoxic payload inside the cell that kills TROP2-expressing cells.
HER2-directed biologic intended to target HER2-expressing tumor cells; the exact modality is not specified in the record.
Bispecific anti-HER2 antibody-drug conjugate (anbenitamab linked to a topoisomerase-1 inhibitor). Binds two distinct HER2 epitopes on tumor cells, is internalized, and releases the topo-1 inhibitor payload, which stabilizes DNA–topoisomerase-1 cleavage complexes, prevents DNA re-ligation, induces DNA strand breaks, leading to cell-cycle arrest and apoptosis in HER2-expressing cells.
ADC binds HER2 on tumor cells, is internalized, and releases a topoisomerase‑1 inhibitor that stabilizes topo‑1–DNA cleavage complexes, causing DNA strand breaks, cell‑cycle arrest, and apoptosis.
Autologous gene-modified T cells engineered to express a chimeric antigen receptor targeting B7-H3 (CD276); upon antigen engagement, CAR signaling (CD3ζ with costimulatory domains) activates T cells to proliferate, release cytokines, and kill B7-H3–expressing tumor cells. Administered intraperitoneally or intravenously.
Autologous T cells are engineered to express a chimeric antigen receptor targeting B7-H3 (CD276). Upon binding B7-H3 on tumor cells, CAR signaling (CD3ζ with costimulatory domains) activates the T cells to proliferate, release cytotoxic cytokines, and mediate direct tumor cell lysis.
CAR T cells bind B7-H3 on target cells, activating CD3ζ/costimulatory signaling to induce cytolysis via perforin/granzyme release and death-receptor pathways.